Equities

Hikma Pharmaceuticals PLC

Hikma Pharmaceuticals PLC

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (GBX)1,658.50
  • Today's Change-4.00 / -0.24%
  • Shares traded787.86k
  • 1 Year change-19.49%
  • Beta0.3523
Data delayed at least 20 minutes, as of Mar 20 2023 17:34 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Key statistics

On Monday, Hikma Pharmaceuticals PLC (HIK:LSE) closed at 1,658.50, -22.39% below its 52-week high of 2,137.00, set on Mar 25, 2022.
52-week range
Today
1,174.50Oct 24 20222,137.00Mar 25 2022
Short selling activity
Low
Med
High
Provided by S&P Global Market Intelligence
Open1,655.50
High1,675.00
Low1,637.50
Bid1,195.00
Offer1,666.00
Previous close1,662.50
Average volume451.19k
Shares outstanding220.26m
Free float154.80m
P/E (TTM)24.36
Market cap3.64bn GBP
EPS (TTM)0.6787
GBP
Annual div (ADY)46.95
GBX
Annual div yield (ADY)2.82%
Div ex-dateAug 18 2022
Div pay-dateSep 20 2022
Next div ex-dateMar 23 2023
Next div pay-dateMay 05 2023
Data delayed at least 20 minutes, as of Mar 20 2023 17:34 BST.
More ▼

Investors Chronicle View

The last IC recommendation on Hikma Pharmaceuticals PLC shares was Hold at 1.00 on 23 Feb 2023Read the full article

Board of Directors

1/12

Said Darwazah, Executive Chairman and CEO

2/12

Mazen Darwazah, Executive Vice Chairman, President of MENA

3/12

Ali Al-Husry, Non-Executive Director

4/12

Pat Butler, Nomination and Governance Committee Chairman, Senior Independent Non-Executive Director

5/12

John Castellani, CREC Chairman, Independent Non-Executive Director

6/12

Nina Henderson, Remuneration Committee Chairman, Independent Non-Executive Director

7/12

Cynthia Flowers, Independent Non-Executive Director

8/12

Douglas Hurt, Audit Committee Chairman, Independent Non-Executive Director

9/12

Laura Balan, Independent Non-Executive Director

10/12

Victoria Hull, Independent Non-Executive Director

11/12

Deneen Vojta, Independent Non-Executive Director

12/12

Hussein Arkhagha, Chief Counsel and Company Secretary

Contact

Address:
Hikma Pharmaceuticals PLC
1 New Burlington Place
London
W1S 2HR

T: +44 (0) 20 7399 2760
F: +44 (0) 20 7399 2761
E: investors@hikma.uk.com
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.
S&P Global Market Intelligence Short Selling Activity © S&P Global Market Intelligence. All rights reserved.
Although S&P Global Market Intelligence has made every effort to ensure this data is correct, nevertheless no guarantee is given to the accuracy or completeness. Any opinions or estimates expressed herein are those of S&P Global Market Intelligence on the date of preparation and are subject to change without notice; however no such opinions or estimates constitute legal, investment or other advice. You must therefore seek independent legal, investment or other appropriate advice from a suitably qualified and/or authorised and regulated advisor prior to making any legal, investment or other decision. This is intended for information purposes only and is not intended as an offer or recommendation to buy, sell or otherwise deal in securities.